Research programme: interleukin-2 analogue - Pivotal BioSciencesAlternative Names: PB 101- Pivotal BioSciences; PB1
Latest Information Update: 15 Jun 2010
At a glance
- Originator University of Southern California
- Class Antineoplastics
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 15 Jun 2010 Preclinical development is ongoing in USA
- 12 May 2004 Preclinical trials in Cancer in USA (unspecified route)